N-cyclohexyl-2-{4-[3-methoxy-4-(4-methylimidazol-1-yl)-phenyl]-1,2,3-triazol-1-yl}-N-phenylacetamide | 1093975-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-cyclohexyl-2-{4-[3-methoxy-4-(4-methylimidazol-1-yl)-phenyl]-1,2,3-triazol-1-yl}-N-phenylacetamide
• 英文别名: N-cyclohexyl-2-[4-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]triazol-1-yl]-N-phenylacetamide
• CAS: 1093975-41-7
• 化学式: C₂₇H₃₀N₆O₂
• 分子量: 470.574
• InChiKey: OSWRMNQCTUFSFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-甲氧基-4-氟苯甲醛 在 potassium carbonate 、 copper(II) sulfate 、 sodium ascorbate 作用下， 以 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-cyclohexyl-2-{4-[3-methoxy-4-(4-methylimidazol-1-yl)-phenyl]-1,2,3-triazol-1-yl}-N-phenylacetamide
  参考文献：
  名称：

  Triazoloamides as potent γ-secretase modulators with reduced hERG liability

  摘要：

  Synthesis and SAR studies of novel aryl triazoles as gamma secretase modulators (GSMs) are presented in this communication. Starting from our aryl triazole leads, optimization studies were continued and the series progressed towards novel amides and lactams. Triazole 57 was identified as the most potent analog in this series, displaying single-digit nanomolar A beta 42 IC50 in cell-based assays and reduced affinity for the hERG channel. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.054

文献信息

• TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS
  申请人：Fischer Christian

  公开号：US20100222320A1

  公开（公告）日：2010-09-02

  Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.

  公式为I的化合物：选择性地减弱Aβ（1-42）的产生，因此可用于治疗或预防与Aβ在大脑中沉积相关的疾病，特别是阿尔茨海默病。
• WO2008/156580
  申请人：——

  公开号：——

  公开（公告）日：——
• US8242150B2
  申请人：——

  公开号：US8242150B2

  公开（公告）日：2012-08-14
• [EN] TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS<br/>[FR] DÉRIVÉS DU TRIAZOLE DESTINÉS AU TRAITEMENT DE LA MALADIE D'ALZHEIMER ET D'ÉTATS ASSOCIÉS
  申请人：MERCK & CO INC

  公开号：WO2008156580A1

  公开（公告）日：2008-12-24

  [EN] Compounds of formula I: Selectively attenuate production of Aß(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aß in the brain, in particular Alzheimer's disease.
  [FR] L'invention porte sur des composés de la formule 1 qui atténuent sélectivement la production de Aß(1-42) et, par conséquent, trouvent leur utilité dans le traitement et la prévention de maladies associées au dépôt d'Aß dans le cerveau, en particulier la maladie d'Alzheimer.
• Triazoloamides as potent γ-secretase modulators with reduced hERG liability
  作者：Christian Fischer、Susan L. Zultanski、Hua Zhou、Joey L. Methot、Sanjiv Shah、Hugh Nuthall、Bethany L. Hughes、Nadja Smotrov、Armetta Hill、Alexander A. Szewczak、Christopher M. Moxham、Nathan Bays、Richard E. Middleton、Benito Munoz、Mark S. Shearman

  DOI：10.1016/j.bmcl.2012.03.054

  日期：2012.5

  Synthesis and SAR studies of novel aryl triazoles as gamma secretase modulators (GSMs) are presented in this communication. Starting from our aryl triazole leads, optimization studies were continued and the series progressed towards novel amides and lactams. Triazole 57 was identified as the most potent analog in this series, displaying single-digit nanomolar A beta 42 IC50 in cell-based assays and reduced affinity for the hERG channel. (C) 2012 Elsevier Ltd. All rights reserved.